Merck's hep C combo hits cure-rate goal in IV drug users; Meda's Elidel could suffer on Valeant pharmacy snafu;

> Merck & Co.'s ($MRK) forthcoming hepatitis C regimen got a boost from new data showing that it delivered a high cure rate in patients who use intravenous drugs, the "hot core" of people with the disease. Report

> Sweden's Meda, whose dermatology drug Elidel is licensed in the U.S. to Valeant Pharmaceuticals ($VRX), could see sales disruptions from its partner's specialty pharmacy woes. Report

> Gilead Sciences ($GILD) won expanded FDA approval for its blockbuster hepatitis C combo pill Harvoni, extending use to new subtypes of hep C and to patients co-infected with HIV. Report

And Finally... Professional cycling's Team Novo Nordisk met with Pope Francis for World Diabetes Day last week. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

COVID-19 vaccine makers' recent safety pledge continues to increase positive sentiment among Americans, new Harris Poll data say.

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.